![Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study - The Lancet Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study - The Lancet](https://www.thelancet.com/cms/attachment/2000987067/2003627365/gr1.gif)
Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study - The Lancet
![High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram. - Abstract - Europe PMC High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6709482/bin/AAC.00634-19-f0001.jpg)
High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram. - Abstract - Europe PMC
![PDF] Response of Vancomycin according to Steroid Dosage in Pediatric Patients with Culture-Proven Bacterial Meningitis | Semantic Scholar PDF] Response of Vancomycin according to Steroid Dosage in Pediatric Patients with Culture-Proven Bacterial Meningitis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e5702316a28afd612997701f433e2fcb6228312a/2-Table1-1.png)
PDF] Response of Vancomycin according to Steroid Dosage in Pediatric Patients with Culture-Proven Bacterial Meningitis | Semantic Scholar
![Ceftriaxone 1 g Versus 2 g Daily for the Treatment of Enterobacterales Bacteremia: A Retrospective Cohort Study - Nadeem Baalbaki, Sharon Blum, Meredith Akerman, Diane Johnson, 2022 Ceftriaxone 1 g Versus 2 g Daily for the Treatment of Enterobacterales Bacteremia: A Retrospective Cohort Study - Nadeem Baalbaki, Sharon Blum, Meredith Akerman, Diane Johnson, 2022](https://journals.sagepub.com/cms/10.1177/87551225221121252/asset/images/large/10.1177_87551225221121252-fig1.jpeg)
Ceftriaxone 1 g Versus 2 g Daily for the Treatment of Enterobacterales Bacteremia: A Retrospective Cohort Study - Nadeem Baalbaki, Sharon Blum, Meredith Akerman, Diane Johnson, 2022
![High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram | Antimicrobial Agents and Chemotherapy High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram | Antimicrobial Agents and Chemotherapy](https://journals.asm.org/cms/10.1128/aac.00634-19/asset/f798dccd-aff5-4381-a9d9-8ba4ce6cf677/assets/graphic/aac.00634-19-t0001.jpeg)
High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram | Antimicrobial Agents and Chemotherapy
![5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study - The Lancet 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study - The Lancet](https://www.thelancet.com/cms/attachment/2001012165/2003802982/gr1.gif)
5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study - The Lancet
![RWJMS Infectious Diseases on X: "Ever wondered why we dose ceftriaxone @ 2g q12h for meningitis? #IDtwitter https://t.co/aFIwlMZ60R" / X RWJMS Infectious Diseases on X: "Ever wondered why we dose ceftriaxone @ 2g q12h for meningitis? #IDtwitter https://t.co/aFIwlMZ60R" / X](https://pbs.twimg.com/media/FZLIXbOVsAAxlOK.jpg:large)
RWJMS Infectious Diseases on X: "Ever wondered why we dose ceftriaxone @ 2g q12h for meningitis? #IDtwitter https://t.co/aFIwlMZ60R" / X
![High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram | Antimicrobial Agents and Chemotherapy High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram | Antimicrobial Agents and Chemotherapy](https://journals.asm.org/cms/10.1128/aac.00634-19/asset/13495456-a293-4396-a596-325496177da1/assets/graphic/aac.00634-19-f0003.jpeg)